Kornimate/medical-research-clean huggingface dataset:
urethral functional profile length before radical prostatectomy as an early postoperative continence predictor

Conditions: Urinary Incontinence

Summary: urinary incontinence (ui) is one of the most common complications of radical prostatectomy (rp). impaired urethral sphincter function is generally considered to be the most important contributing factor of ui however, the mechanism of onset and recovery of urinary continence has not been fully elucidated. in this research, the urodynamic method of urethral pressure profile (upp) was used to evaluate functional urethral length (ful) and maximal urethral closure pressure (mucp) and correlate with the postprostatectomy continence recovery. objective of this research is to evaluate preoperative ful and mucp as an early continence recovery predictors after open retropubic rp (orrp). the research was conducted at the department of urology of the university hospital centre zagreb on a group of 43 patients in the period from july 15th , 2019 to may 07th , 2021.the severity of ui and bothersome were assessed using fully validated international consultation on incontinence questionnaire - urinary incontinence short form (iciq-ui sf) and number of pads used in 24h. patients were interviewed about the use of urinary pads and asked to fill out the iciq-ui sf before and 2, 8, 16 and 24 weeks after rp.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed with localized prostate cancer 2. open retropubic radical prostatectomy (orrp) is planned as a treatment exclusion criteria: 1. incontinent patients prior to orrp 2. previous surgery in the area of the prostatic urethra 3. previous procedures that can damage the innervation of the pelvis 4. radiotherapy performed in the pelvic area prior to orrp 5. adjuvant radiotherapy in the first postoperative year

Keywords: urinary incontinence radical prostatectomy urethral pressure profile iciq-ui sf pads
evaluating safety and efficacy of repeat doses of ub-621in adult patients with recurrent genital herpes

Conditions: Recurrent Genital Herpes

Summary: to evaluate the efficacy of repeat-dose ub-621 for the recurrent genital hsv-2 infection to evaluate the safety and tolerance of repeat-dose ub-621 for the recurrent hsv-2 infection to evaluate the pharmacokinetics of repeat-dose ub-621 in rgh patients


Eligibility criteria:
inclusion criteria: 1. age ≧18 years at the time of signing icf 2. hsv-2 seropositive when screening 3. a history of recurrent genital herpes and experience 6-12 episodes in the past year 4. negative result of the hiv assay 5. in baseline period, subject have to present at the site within 72 hours after the occurrence of new lesions 6. keep daily diary during the study period 7. female subjects: negative serum β-hcg at screening and no beast-feeding. 8. use contraception during study participation 9. understanding and willing to fully comply with study interventions and restrictions. exclusion criteria: 1. any medical conditions that may interfere the assessment of ub-621efficacy, or any medical conditions that may present symptoms in the anogenital regions (such as syphilis, genital warts). 2. history of malignancy, diabetes, auto-immune diseases or immunodificiency diseases. 3. use of systemic steroids or immunomodulators within 30 days prior to the screening 4. participating any clinical trials within 30 days prior to the screening, or within 5 half-life of any investigational drugs, take the longer. 5. vaccination within 30 days prior to the screening. 6. prior exposure to any hsv vaccines 7. known hypersensitive to monoclonal antibodies 8. ecg abnormalities with clinical relevance or cardiovascular diseases at screening 9. serum creatinine \> 1.5 mg/dl at screening 10. ast and alt \> 2.5 x uln at screening 11. hbsag positive or hct antibody positive at screening 12. syphilis rpr test positive at screening 13. tb history or documented t-spot positive, or now is under treatment of tb 14. any other circumstances that are determined to affect the conduct or successful completion of the clinical study
phase iii general clinical study of npo-11 in patients undergoing gastric endoscopy

Conditions: Stomach Diseases

Summary: patients who require gastric endoscopy, including the patient population\* excluded from the phase iii controlled clinical study of npo-11, will receive an intragastric single dose of npo-11 20 ml. the efficacy of npo-11 as a premedication for endoscopy will be evaluated based on the percentage of patients having no gastric peristalsis at both 2 minutes post-dose and the end of endoscopy (primary outcome measure). the safety of npo-11 will be evaluated based on adverse events and adverse drug reactions (adrs) observed between administration and seven days after administration. patient population excluded from the phase iii controlled clinical study of npo-11 * patients with reflux esophagitis * patients with active gastric or duodenal ulcers * patients who undergo endoscopy under sedation * patients who undergo endoscopy with a scope of \<9 mm in diameter


Eligibility criteria:
inclusion criteria: inpatients or outpatients of either sex who meet criteria (1) and (2) below will be enrolled in the study. patients have to provide written informed consent for voluntary participation in the study. 1. patients who require gastric endoscopy (except for emergency endoscopy or endoscopy for comprehensive medical examination) 2. patients who are older than 20 years at the time of consent exclusion criteria: patients who meet any of the following criteria will be excluded from the study. the criteria (2) and (3) will be confirmed during endoscopy. patients who meet any of these criteria will be withdrawn from the study at the time of confirmation. 1. patients with a history of surgery to the stomach 2. patients with severe gastric stenosis or deformation which makes observation of gastric peristalsis difficult 3. patients with upper gastrointestinal bleeding which requires hemostasis 4. patients on cancer treatment (chemotherapy or radiotherapy) 5. patients with a history of shock or hypersensitivity to l-menthol or peppermint oil (mint oil) 6. patients with a history of shock or hypersensitivity to lidocaine hydrochloride 7. pregnant or lactating women, women of childbearing potential, or women who plan to become pregnant during the study 8. patients who have been exposed to npo-11 9. patients who have received other investigational drugs within four months before consent or who are participating in other clinical studies 10. patients otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion

Keywords: patients undergoing gastric endoscopy
position and esophageal pressure

Conditions: Acute Respiratory Distress Syndrome

Summary: esophageal pressure measurements are used in moderate/severe accurate respiratory distress syndromeards patients in order to set ventilator settings. there might be variations of the measured value according to the patient position (0° vs 30°) at the time of measurements.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * acute respiratory failure defined by pao2/fio2\ 45mmhg or moderate or severe accurate respiratory distress syndrome ards defined by: * new or worsening respiratory symptoms in the previous week. * bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules * respiratory failure not fully explained by cardiac failure or fluid overload * pao2/fio2\< 200 mmhg and peep ≥ 5 cm h2o and vt ≤6 ml/kg of ideal body weight * patient intubated or tracheotomized and receiving mechanical ventilation * indication of esophageal measurement decided by the clinician exclusion criteria: * contraindication to naso-gastric tube insertion : * recent gastro-duodenal ulcer * stage iii esophageal varices * refractory intracranial hypertension * unstabilized spine fracture * surgical contraindication * burns on more than 20 % of the body surface * underlying disease with a life expectancy of less than one year * end-of-life decision before inclusion * pregnant or breast-feeding patients * subject deprived of freedom, minor, subject under a legal protective measure * research team unavailability * lack of medical care plan

Keywords: position patient esophageal pressure
long antagonist protocol for ivf with single luteal dose of degarelix

Conditions: Pregnancy, Ovarian

Summary: a prospective study of three different doses of degarelix in late luteal phase of women undergoing ovarian stimulation for ivf

a prospective study of three different doses of degarelix in late luteal phase of women undergoing ovarian stimulation for ivf:single dose of degarelix 24mg, 16mg and 12 mg, on day 24th of previous luteal face cycle. on day 2 of the cycle: will be measured: lh levels, estradiol levels, and fsh levels. on day 1 of the stimulation (depending day of the cycle): will be measured: lh levels, estradiol levels, and fsh levels. on day 6 of the stimulation( depending day of the cycle):will be measured: lh levels, estradiol levels, and fsh levels. on day 8 of the stimulation( depending day of the cycle):will be measured: lh levels, estradiol levels, and fsh levels. on day 10 of the stimulation( depending day of the cycle):will be measured: lh levels, estradiol levels, and fsh levels.

Eligibility criteria:
inclusion criteria: * primary infertility * age 18-39 years; body mass index (bmi) 18-29kg/m2; * regular menstrual cycle of 26-35days, * presumed to be ovulatory; * early follicular- phase serum concentration of fsh within normal limits (1-12 iu/l). exclusion criteria: * women with diabetes and other metabolic disease * women with heart disease, qt prolongation,heart failure * elevated liver enzymes, liver failure, hepatitis * women with inflammatory or autoimmune disease * abnormal karyotype; * polycystic ovarian syndrome, * endometriosis stage iii/iv; * history of being a 'poor responder', * defined as \>20 days of gonadotrophin in a previous stimulation cycle, or any previous cancellation of a stimulation cycle due to limited follicular response, or development of less than 4 follicles 15 mm in a previous stimulation cycle; history of recurrent miscarriage; severe ohss in a previous stimula- tion cycle or any contraindication for the use of gonadotrophins.
meta-analysis of stannous fluoride and the effects on gingival health

Conditions: Gingivitis

Summary: the aim of this 18 study analysis was to compare the effect of bioavailable stannous fluoride (snf2) dentifrices when used up to 3 months on gingivitis relative to a positive or negative control dentifrice.


Eligibility criteria:
subjects were excluded from this study for the following reasons; * pregnancy, * rampant caries, * severe periodontitis, * at discretionary of the principal investigator.
effects of osteopathic manipulations and muscle training on the myoelectric activity of the pelvic floor

Conditions: Urinary Incontinence

Summary: the objective of this study was to compare the effects of four different interventions on pelvic floor muscle electromyographic activity in women with stress urinary incontinece: i) a global osteopathic protocol (myofascial, visceral, and articular techniques), ii) one manipulation technique (high velocity, low amplitude (hvla)/thrust) of the sacroiliac joint and t10-l2, iii) pelvic floor muscle training, and iv) a control group with no intervention. the hypothesis is that the global osteopathic protocol and hvla technique can increase pelvic floor muscle electromyographic activity to a level greater than or equal to the standard care established in the literature (pelvic floor muscle training).

participants represented a convenience sample and were recruited from hospitals, urogynecology doctors' clinics, invitations via social networks, gyms, clubs, and sports consultants. women had to be between 30 and 60 years old and report symptoms of urine loss due to exertion in the last six months.the participants were randomly allocated into four groups (g1 = intervention using an hvla/thrust technique for the sacroiliac and t10-l2 joints, g2 = global osteopathic protocol, g3 = pft, and g4 = control) by a blinded researcher with a spreadsheet of random numbers.the primary outcome measure was surface electromyography (emg) performed at five different times: before the intervention and immediately, 30 minutes, 60 minutes, and four weeks after. this evaluation was performed by a physiotherapist with ten years of experience in urogynecology and expertise in pfm electromyographic evaluation who was blinded to the group allocation.

Eligibility criteria:
inclusion criteria: * symptoms of urine loss due to exertion in the last six months. exclusion criteria: * urgent or mixed urinary incontinency * overactive bladder * neurological disorder * urinary or anal infection * urogenital atrophy * pelvic organ prolapse grade 3 or 4 * sensory pathways and motor not intact * spine fracture

Keywords: pelvic floor training osteopathy urinary incontinence
development and application of a diagnosis and treatment system for children's brain diseases based on knowledge graphs and large models

Conditions: Cerebral Palsy; Mental Retardation; Tourette&#39;s Syndrome; Attention Deficit Hyperactivity Disorder; Autism Spectrum Disorders

Summary: using the knowledge graph and big model technology of combining chinese and western medicine we construct a popularization and prevention system for childhood encephalopathy an assisted decision-making system for childhood encephalopathy and a follow-up tracking question and answer system for childhood encephalopathy patients.


Eligibility criteria:
inclusion criteria: * 1. meet diagnostic criteria for cp id td adhd asd; 2. gender is not limited; exclusion criteria: * 1. cp id td asd due to chorea hepatomegaly hearing abnormality and pharmacogenetic factors; * 2. children with other major mental illnesses (e.g. schizophrenia) or organic diseases (e.g. congenital heart disease);
long term effects of lutein/zeaxanthin and omega-3- supplementation on optical density of amd patients (lutega)

Conditions: Age Related Maculopathy

Summary: the primary objective of lutega is it to determine the long term effect (about 1 year) of the supplementation with a fixed combination of lutein/zeaxanthin and omega-3- fatty acids on the optical density (od) of macular pigment in patients with non- exudative age related maculopathy. furthermore, it is to be examined whether changes of the optical density are different dosages dependent. possible changes of lipofuscin content and effect on drusen in amd patients are studied. the measurement of optical density of macular pigment uses the 1- wavelength reflection method recording reflection images at 460 nm by a fundus camera. the patients are investigated at baseline and are followed up over one year in four more visits. in addition to the od- measurement each examination includes standardized visual acuity test (etdrs), amsler- grid, slit lamp biomicroscopy, fundus photography (color and autofluorescence) and a blood sample.


Eligibility criteria:
inclusion criteria: * all non- exudative forms of age related maculopathy exclusion criteria: * exudative age related maculopathy
the effect of androgen and growth hormone on height and learning in girls with turner syndrome

Conditions: Turner Syndrome

Summary: the purposes of this study are to learn whether treatment with an androgen type hormone will improve the visual-spatial problems associated with turner syndrome, and to evaluate the effect growth hormone, with and without androgen, has on growth.

turner syndrome is associated with short stature, multiple physical stigmata, absent pubertal development, and increased learning problems. this study is designed to (1) examine the effects of sex steroids (androgen and estrogen) on multiple variables including growth rate, gh binding protein, igf-i, igfbp3, and cognitive function in the setting of supplemental growth hormone administration and (2) to investigate any synergistic or additive effects of the androgen and estrogen combination versus each alone, on the above variables.

Eligibility criteria:
* karyotype diagnosis compatible with turner syndrome, but no presence of any y material in the peripheral karyotype unless a gonadectomy has been performed; * chronological age between 10.0 and 14.9 years; * bone age less than or equal to 12 years; and * no treatment with estrogen, androgen, growth hormone, or any other growth-promoting agents exceeding 12 months, and no treatment with any of these agents in the previous 3 months.

Keywords: turner syndrome estrogen androgen growth hormone
the effect of breastfeeding support system

Conditions: Preterm; Breastfeeding; Breast Milk; Breastfeeding Support System

Summary: this study aimed to examine the impact of a breastfeeding support system on breast milk production and mother-infant bonding in preterm infants. the sample included 70 preterm infants and their mothers, divided into two groups: 35 in the control group and 35 in the experimental group, all of whom met the study criteria.


Eligibility criteria:
inclusion criteria: for the infant: gestational age between 30 and 34 weeks birth weight of 1000 g or more for the mother: age over 18, literate, and able to speak turkish willingness to breastfeed and no chronic illness preventing breastfeeding exclusion criteria: infants without identification infants with unstable vital signs mothers with conditions that prevent breastfeeding
qigong for multiple sclerosis: a feasibility study

Conditions: Multiple Sclerosis

Summary: this feasibility study explores a community-based qigong intervention for people with multiple sclerosis (ms). the primary aim is to assess the feasibility of weekly community qigong classes for people with ms. the secondary aim is to explore the effects of qigong on balance, gait, mood, fatigue, and quality of life.

qigong, a traditional chinese mind-body exercise, has been shown to improve balance and gait in several neurological conditions; however, community-delivered qigong has never been assessed for people with multiple sclerosis (ms). we assessed the feasibility of community qigong classes for people with ms and explored outcomes of balance, gait, and quality of life (qol). twenty adults with ms were randomly assigned to 10 weeks of community qigong classes or wait-list control. feasibility criteria included recruitment, retention, adherence, and ability to participate in qigong movements. secondary outcome measures included physical tests of mobility, gait and balance, and participant-reported mobility, depression, anxiety, fatigue, and qol. because this is a small feasibility study, the data collected are meant to be hypothesis-generating. any clinically meaningful trends toward improvement will justify further exploration of qigong for ms in a larger clinical trial.

Eligibility criteria:
inclusion criteria: * living in the portland metropolitan area * self-reported diagnosis of multiple sclerosis (ms - any type) * demonstrated ability to walk 50 feet without assistance * stable on disease-modifying or balance medications three months prior to baseline exclusion criteria: * pregnant or nursing * participated in qigong, tai chi, or yoga (\>1 month) within six months prior to baseline * had an ms relapse within 30 days prior to baseline.

Keywords: qigong pragmatic design gait multiple sclerosis
healthy lifestyle intervention on diabetes risk reduction among bruneian young adults

Conditions: Overweight and Obesity; Risk Reduction; Diabetes Mellitus, Type 2

Summary: the general research question posed was 'how effective is a healthy lifestyle intervention using behavioural change strategies in the prevention of type 2 diabetes mellitus (t2dm)?'. the main aim was to assess the effectiveness of a healthy lifestyle intervention implemented for 12 weeks via face-to-face group sessions and by using social media tools (facebook and whatsapp) for young adults at risk of t2dm. the hypothesis was that this healthy lifestyle intervention may be effective in terms of initiating an increased physical activity (pa) level and a healthy balanced dietary intake resulting in improvements of other t2dm risk factors at 12 weeks.

the specific research question posed was 'is a healthy lifestyle intervention using social cognitive theory (sct)-based pa and dietary strategies implemented for 12 weeks through face-to-face group sessions and social media tools effective in the initiation and maintenance of increased pa level and healthy balanced dietary intake, resulting in improvements of t2dm risk score, anthropometrics, metabolic parameters and sct-related psychosocial factors among bruneian young adults at risk of t2dm?'. study design was two-arm parallel, stratified with simple randomisation, and assessor-blinded randomised controlled trial. participants were randomly allocated into intervention group and control group. participants were students and alumni of universiti brunei darussalam and universiti teknologi brunei who were overweight-obese at risk of t2dm with a mean age of 23.1 (2.48) years old. intervention group went through a healthy lifestyle intervention using evidence-based sct strategies emphasising on pa and diet for 12 weeks, while the control group only received leaflets on healthy lifestyle with no further guidance. outcomes measured were changes from baseline at week 0 to post-intervention at week 13 between intervention and control groups. outcomes were changes in diabetes risk score, anthropometrics, metabolic parameters, pa, dietary intake and sct-related psychosocial factors, with repeated-measures anova as the main analysis.

Eligibility criteria:
inclusion criteria: * bruneian including permanent residents * bmi from 25.00 to 39.99 kg/m2 * american diabetes association (ada) diabetes risk score of at least 3 and maximum score of 8 * mentally and physically fit with no chronic conditions * without medical conditions that could influence glucose metabolism and insulin resistance * answered 'no' to all 6 questions in questionnaire-based pre-exercise risk assessment * not actively participating in other healthy lifestyle programmes * had access to computer or mobile phone with internet

Keywords: social cognitive theory type 2 diabetes mellitus social media diabetes prevention lifestyle intervention